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Abstract: Neuroregeneration is the regrowth or repair of nervous tissues, cells, or cell products 
involved in neurodegeneration and inflammatory diseases of the nervous system like Alzheimer’s 
disease and Parkinson’s disease. Nowadays, application of nanotechnology is commonly used 
in developing nanomedicines to advance pharmacokinetics and drug delivery exclusively for 
central nervous system pathologies. In addition, nanomedical advances are leading to therapies 
that disrupt disarranged protein aggregation in the central nervous system, deliver functional 
neuroprotective growth factors, and change the oxidative stress and excitotoxicity of affected 
neural tissues to regenerate the damaged neurons. Carbon nanotubes and graphene are allotropes 
of carbon that have been exploited by researchers because of their excellent physical properties 
and their ability to interface with neurons and neuronal circuits. This review describes the role of 
carbon nanotubes and graphene in neuroregeneration. In the future, it is hoped that the benefits 
of nanotechnologies will outweigh their risks, and that the next decade will present huge scope 
for developing and delivering technologies in the field of neuroscience.
Keywords: neuroregeneration, neurodegeneration, nanomedical, carbon nanotube, graphene, 
nanodrug delivery
Introduction
Neurodegenerative pathologies occur when the basic units of the nervous system, 
ie, neurons in the brain and spinal cord, start to deteriorate. Alterations in these nerve 
cells cause them to function abnormally, which results in the demise of the cell. Initial 
symptoms of neuronal deterioration may include loss of coordination or the ability to 
remember names. These problems progress to an advanced stage if a large number of 
neurons deteriorate. The patients may lose the ability to think and move on their own, 
and these disease are mostly incurable.1,2
Neurodegenerative diseases affect over 90,000 people every year. Among the 
neurodegenerative diseases, spinal cord injuries alone affect 10,000 people each year. 
Neurodegenerative pathologies affect millions of people worldwide. Alzheimer’s dis-
ease (AD) and Parkinson’s disease (PD) are the most common neurological diseases 
and occur in 5 million and 1.2 million Americans, respectively.3 If left unchecked, 
30 years from now it is expected that more than 12 million Americans will suffer from 
neurodegenerative disease. Therefore, there is an urgent need to find therapies and a 
cure for these neurodegenerative pathologies.4,5
Neuroregeneration is the restoration of neurons that have deteriorated as a result 
of neurodegenerative diseases. Neuroregeneration denotes the regrowth or repair of 
degenerated nervous tissues and nerve cells involved in the production of new neurons, 
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glia, axons, myelin, and synapses. The functional mechanism 
of neuroregeneration differs between the peripheral nervous 
system (PNS) and the central nervous system (CNS). While 
the PNS has an inherent capability for self-repair and regen-
eration, the CNS is unable to self-repair and regenerate.6 
Neuroregeneration is significant clinically, because it is a 
regenerative mechanism involving the damaged neuron that 
provides mechanical support for regeneration (Figure 1).
The development of nanomaterials, especially carbon 
nanotubes (CNTs) and graphene, which can advance 
neuronal growth, is likely to have a major impact on neu-
roregenerative techniques used in the future for neurodegen-
erative pathologies such as AD and PD. This paper reviews 
the most common degenerative pathologies and discusses the 
application of CNTs and graphene nanomaterials as tissue 
engineering scaffolds for neuroregeneration and nanodrug 
delivery aiming at neuroprotection and functional regenera-
tion of neurons in the CNS.
Neurological disorders
The basic unit of the brain is the neuron, which consists of a 
cell body, dendrites, and a longer extension of the cell body 
known as the axon. The dendrites transmit signals from their 
tips toward the neuron cell body, whereas the axon carries 
messages away from the cell body toward the terminal end of 
the axon. The distal tips of the axon are used to communicate 
with other cells, eg, effector cells. Bundles of axons from 
a collection of neurons are called nerves, which transmit 
signals in the same direction and serve as an intermediary 
connection between the brain and effector cells. Thus, if there 
is any damage to the nerve, transmission of signals between 
the cell body and effector cells is interrupted, and the neurons 
are unable to convey signals effectively.
Neurological disorders result from functional abnormality 
or disturbance of the nervous system, are assessed by neu-
rological examination, and are treated within the specialties 
of neurology and clinical neuropsychology. AD and PD are 
the most common types of neurodegenerative disease7 and 
are briefly outlined in this review. Common mechanisms of 
neurodegeneration include dysfunction of the mitochondria, 
increased oxidative stress levels, excitotoxicity, aggregation 
of proteins, accumulation of iron, and inflammatory changes 
(Figure 2).
Alzheimer’s disease
AD is thought to have a genetic basis in approximately 
70% of cases, and is characterized by loss of neurons and 
synapses in the cerebral cortex and subcortical areas. This 
loss of neurons may result in degeneration of the affected 
area, including the temporal lobe, parietal lobe, parts of the 
frontal cortex, and the cingulate gyrus.8 Accumulation of 
unusually folded amyloid beta and tau proteins in the brain 
leads to formation of plaques that cause AD, with the disease 
now being recognized as a protein misfolding condition, ie, 
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Carbon nanotubes and graphene in neuroregeneration
Figure 2 Common mechanisms involved in neurodegeneration.
a proteopathy.9 These plaques are made up of small peptides 
and amino acids called amyloid beta, which is part of the 
larger amyloid precursor protein that penetrates through 
the membrane of the neuron and is an important factor for 
the growth of the neuron and post-injury repair.10,11
Parkinson’s disease
Also known as idiopathic or primary parkinsonism, hypoki-
netic rigid syndrome, or paralysis agitans, PD is the second 
most widespread neurodegenerative disorder and manifests 
as bradykinesia, rigidity, resting tremor, and postural instabil-
ity. PD is a degenerative pathology of the CNS and occurs as 
a result of death of dopamine-generating cells in the midbrain, 
mainly those in the substantia nigra. The cause of this cell 
death is unknown. Possible diagnostic approaches include 
detection of biomarkers and the molecular mechanisms 
leading to PD. Therapeutic goals for PD involve neuropro-
tection, eg, preventing injury caused by free radicals and 
lowering levels of metal ions in the brain by administration 
of chelators, as well as neuroregeneration, eg, activation of 
neuronal progenitor cells and more effective drug delivery 
systems that can penetrate the blood–brain barrier. Nanotech-
nology has a key role in developing these new diagnostic and 
therapeutic tools for PD.12 Accumulation of alpha-synuclein 
protein in the Lewy bodies of neurons, along with inadequate 
formation and activity of dopamine in neurons, is one of the 
major manifestations of the disease.13,14
Role of nanotechnology in 
neuroprotection
Preservation of the structure and function of neurons is 
called neuroprotection. This strategy is a popular choice 
in patients suffering from CNS disorders such as stroke, 
neurodegenerative diseases, and other brain injuries in 
order to halt, or reduce the loss of neurons. The mechanisms 
underlying neurodegeneration are the same in different 
CNS disorders despite their different signs and symptoms.15 
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excitotoxicity that are related to disorders of the CNS. A 
combination of oxidative stress and excitotoxicity causes 
lysis of neurons, and preventing these is an essential aspect 
of neuroprotection. Glutamate antagonists and antioxidants 
are neuroprotective treatments that aim to limit excitotoxicity 
and oxidative stress, respectively.16 Neurons can be protected 
from degenerative disorders by using neuroprotective drugs. 
Steroids such as methylprednisolone can be used to prevent 
secondary damage and to reduce the neuroinflammation 
caused by spinal cord injury, and Sygen® (Fidia SpA, San 
Mauro Torinese, Italy), a recently discovered drug, appears 
to reduce the loss of nerve function.17
The advantages of nanotechnology in the treatment of 
PNS and CNS disorders are enormous, and may eventually 
offer the patient and clinician more treatment options. The 
combination of development of synthetic and characterization 
methods in chemistry and materials science, and improvement 
of nanoengineered applications in the nervous system, along 
with a detailed study of neurophysiology and neuropathology, 
should be done.18 CNTs and graphene are promising candi-
dates in a number of areas of nanomedicine, especially in the 
field of neurology. The applications of CNTs and graphene in 
neuroregeneration and the nanotechnologies used for restor-
ing neuronal cells are discussed in the following sections.
Carbon nanotubes
CNTs are allotropes of carbon with a cylindrical nanostruc-
ture. Nanotubes are part of the fullerene family, members 
of which have a long hollow structure made of sheets one 
atom thick. In the case of CNT, carbon is the atom present 
in these sheets. Once rolled, these sheets become nanotubes. 
The rolling angles are chiral and the radius of the tube deter-
mines the properties of the CNT. CNTs are further classified 
as single-walled nanotubes (SWNTs), which consist of a 
single sheet of carbon rolled up into a tubular-like structure, 
and multi-walled nanotubes (MWNTs), which consist of 
multiple layers of carbon sheets. In the future, CNT-based 
technologies are likely to be particularly useful for promot-
ing functional recovery of neurons after brain damage due 
to the outstanding physical properties of these nanomaterials 
together with their recently documented ability to interface 
with neuronal circuits, synapses, and membranes.19
Pristine CNTs are insoluble in most aqueous solvents, but 
chemical modification or functionalization of the nanotube 
surface may improve their aqueous solubility, enabling their 
use in the treatment of CNS pathology.20 Non-functionalized 
CNTs decrease cell viability, and an inflammatory response 
has been observed with pristine CNTs. CNTs (0.5 mg) have 
toxic effects on the respiratory system, that include forma-
tion of granuloma in the lungs.21 In addition, aggregation of 
CNTs via van der Waals’ interactions can affect profibrogenic 
cellular responses and contribute to the pulmonary toxicity 
of CNTs in vivo.22 Oxidative stress is the main mechanism 
of toxicity, but agglomeration, chirality, and impurities are 
some of the structural and chemical characteristics contribut-
ing to the toxicity of CNTs,23 and it has been reported that 
functionalized CNTs do not have harmful effects.
The above limitations can be resolved by chemical modi-
fication of CNTs, making them a promising nanoengineered 
biomaterial for biomedical application.24,25 CNTs can be 
chemically functionalized covalently or non-covalently.26 The 
mechanism of non-covalent modification is mainly related to 
coating of the CNT using hydrophilic macromolecules such 
as surfactants, polymers, peptides, or single-stranded DNA. 
This coating or wrapping technology enables preservation of 
the aromatic structure of the CNT without harmful effects on 
their electronic characteristics.27 Covalent functionalization 
of CNTs involves chemical reactions, which can be achieved 
in two ways, ie, sidewall covalent conjugation of functional 
groups and oxidation of CNT followed by modification. The 
first approach, ie, sidewall covalent conjugation of organic 
functional groups, may be achieved by chemical reactions, 
particularly 1,3-dipolar cycloaddition of azomethine ylides. 
Georgakilas et al obtained highly soluble CNTs in aqueous 
solution by attaching amino functional groups to the tips and 
sidewalls of the CNTs.20 On the other hand, oxidation and 
further functionalization leads to purified and shorter CNTs. 
Esterification or amidation reactions further derivatize the 
attached carboxylic acid groups into other functional groups. 
Thus, chemical modification of CNTs is a powerful tool that 
can be used to design substrates that can control the growth 
and morphology of neuronal cells.
CNTs in neuroregeneration
Acute neurological disorders are a destructive actions that 
harm human biological functioning. Despite the abundance 
of published studies and established findings, the treatments 
available for neurodegenerative diseases are limited and more 
investigation is needed to explore the mechanisms involved 
in neurological disorders. A large number of CNS patholo-
gies, in particular AD, PD, stroke, traumatic brain injury, 
and spinal cord injury may lead to failure of brain and spinal 
cord cells.28 The two most important approaches to promot-
ing self-repair of damaged axonal connections are regrowth 
of axons and/or reorganization of the neuronal circuitry. 
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Carbon nanotubes and graphene in neuroregeneration
engineering are preservation of neurons (neurorestoration), 
promotion of an environment conducive to regrowth of the 
degenerated neurons (neurogenesis), and reconnection of 
neuronal circuits, followed by promotion of the plasticity of 
neuronal tissue (neuroplasticity).29
The clear understanding of the nervous system and 
improvement of healing approaches for neurological inter-
vention are believed to have a significant effect in neurosci-
ence research due to the advancements in nanomedicine.30 
Zhang et al have demonstrated the electrical conductive 
capacity and strong mechanical properties of CNTs, and 
shown the morphological characteristics of CNTs to be simi-
lar to those of neurons.31 In addition, the structure and dimen-
sions of CNTs resemble those of certain neuronal structures, 
such as ion channels, signaling proteins, and elements of the 
neuronal cytoskeleton. The resemblance of CNTs to these 
neuronal elements may have an additional benefit with regard 
to enhancing neuronal interaction at the molecular level and 
accordingly improve management of the physiological activ-
ity of neurons and processing of neuronal information.32 Matt-
son et al described how hippocampal neurons in rats could 
grow on MWNT coated with 4-hydroxynonenal, a bioactive 
component, and confirmed the biocompatibility of CNT as 
a promising candidate for neuroregeneration.33 Neuronal 
growth patterns and properties, such as length, branching, 
and numbers of growth cones were based on the chemical 
modification techniques used to functionalize the CNT. Of 
the various chemical functionalization methods possible, 
MWNTs coated with poly(ethylene glycol) diamine resulted 
in a higher number of growth cones and neurite branches.34 
In the same way, SWNTs coated with polyethylenimine 
(PEI) promoted growth of neurites and their branches to a 
greater extent than the PEI substrate alone.35 Matsumoto et al 
reported that MWNTs coated with nerve growth factor or 
brain-derived neurotrophic factor could induce growth of 
neurons on a CNT scaffold, and also controlled the differ-
entiation and continued viability of the neurons.36 Lovat et al 
confirmed that elongation of dendrites and hippocampal 
neuron cell adhesion were enhanced by incorporating a 
purified MWNT substrate. Enhancement of dendrite elon-
gation results in improved signal processing of neurons.37 
Similarly, Mazzatenta et al suggested that purified SWNTs 
promote growth of hippocampal neurons and develop the 
neuronal circuits. Increased transmission of electrical signals 
within the neuronal network leads to notable growth of the 
neuronal circuit.38 Jan et al confirmed the compatibility of 
CNT substrates with neural stem cells (NSCs), based on cell 
viability and development of neuronal processes identical 
to those seen with the normally used growth substrate poly-
L-ornithine.39 The efficacy of CNTs was demonstrated by 
successful delivery of NSCs to injured sites of the CNS and 
their differentiation into neurons.
Novel and improved nanoscaffolds have been developed 
to repair or improve the functioning of neural tissue by 
providing mechanical support to the neurons. Because of 
their electrical and mechanical characteristics, along with 
their neuronal biocompatibility, CNTs are considered to be 
promising candidates for neural tissue engineering.40 Roman 
et al demonstrated the applications of CNTs in the treatment 
of neurodegenerative disease. PEG-modified SWNTs were 
successfully used for neuroregeneration in a rat model of 
Sprague Dawley. The efficiency of the CNT technique was 
confirmed by a decrease in the volume of damaged tissue 
and an increase in the number of neurofilaments in the area 
surrounding the site of injury, along with functional healing 
of the rat hind limb. This study confirms that CNT-based 
substrates can promote ongoing regeneration of damaged 
neurons and neural tissues, giving rise to new perspectives 
in the field of neuroregeneration.41
CNTs in drug delivery
Neuroprotection could be achieved in the future by use of 
nanodrug delivery in chronic neurological disorders. Delivery 
of drugs across the blood–brain barrier is attained by the appli-
cation of nanotechnology in therapeutic techniques, known as 
nanomedicine.42 Recent research shows that the nanomedicine 
required for neurodegenerative pathologies is much less 
than that needed for cancer and infectious diseases.43 Thus, 
emerging nanotechnologies for production of neurotrophin 
delivery systems are promising in terms of their ability to 
activate neurotrophin signaling for neuroprotection and 
neuroregeneration.44 Neurotrophins are proteins that were 
initially recognized as being factors related to the survival of 
sympathetic and sensory neurons. Neurotrophins are essential 
for the development and function of neurons in both the CNS 
and PNS, and can be delivered using CNTs.45
The use of CNTs as a delivery mechanism for the treat-
ment of CNS pathology is based on their structural features, 
especially their improved solubility in physiological solvents 
(even though not a heterogeneous solution) due to their func-
tionalization, large surface area, ability to be easily modified 
with drug molecules, and biocompatibility with neural sys-
tems. Zhang et al used SWNT modified with acetylcholine to 
treat AD. After gastric gavage, SWNT doses up to 300 mg/
kg could enable delivery of drug into the lysosomes of neu-
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Dealing with brain tumors is a challenge regardless of the 
therapeutic advances made with the clear understanding of 
carcinogenesis. Anti-tumor drug molecules have low perme-
ability across the blood–brain barrier, and this has opened up 
new possibilities for CNT-based approaches. In one study, 
a drug delivery system using CNTs considerably enhanced 
the effects of CpG oligodeoxynucleotide immunotherapy 
in the treatment of glioma (a tumor arising from the glial 
cells) and preventing tumors.47 CNT-based therapy would 
be useful in the treatment of a number of neurodegenerative 
pathologies. SWNT functionalized with amine groups via 
the amidation reaction enhances the tolerance of neurons to 
ischemic injury. Using this method, neurons are protected 
and their functions are regained with amine-modified SWNT 
without therapeutic or drug molecules. The mechanism via 
which amine-functionalized SWNTs protect neurons is as 
yet unclear.48 A study by Al-Jamal et al demonstrated the 
effectiveness of amino-functionalized MWNTs in delivery of 
small interfering RNA that decreased apoptosis at the injury 
site and promoted recovery in a rodent model of endothelin-1 
stroke.49 The findings of research on the use of CNTs for 
neuroregeneration are summarized in Table 1.
Graphene
Graphene, like CNT, is a form of nanocarbon. Graphene is 
composed of a single layer of carbon atoms arranged in a 
hexagonal honeycomb lattice, and has unique mechanical, 
optical, thermal, electronic, and magnetic properties. A recent 
analysis highlighted the unique properties of graphene 
and their promise in terms of opening up further research 
avenues in neurotherapeutics, including neuro-oncology, 
neuroimaging, neuroregeneration, functional neurosurgery, 
neurointensive care, spinal surgery, and peripheral nerve 
surgery.50 Initial standard testing has already demonstrated 
that new biosensors based on graphene technology have 
improved accuracy in the detection of glucose levels, DNA, 
peptides, and important enzymes involved in the synthesis 
of neurotransmitters, such as acetylcholinesterase.51
The large surface area available and the possibility of 
conjugating different biomolecules onto its surface makes 
graphene a suitable nanoscaffold for holding small-molecule 
drugs, genes, antibodies, proteins, DNAs, and small interfer-
ing RNAs.52 In addition, it is possible to modify the chemical 
structure of graphene by attachment of reactive functional 
groups, such as amino, carboxyl, hydroxyl, alkyl halogen, 
Table 1 evidence for application of carbon nanotubes in neuroregeneration
Type of CNT Findings References
SwNT, MwNT Morphological characteristics of CNT  
were similar to neurons
31
SwNT, MwNT CNT structural features resemble  
neuronal elements
32
MwCT coated with  
4-hydroxynonenal
Compatible for nerve cell growth 33
MwNT coated with  
polyethylenediamine
Large numbers of growth cones  
and neurite branches
34
SwNT chemically functionalized  
with polyethylenimine
Promotes more neuronal branching than  
polyethylenimine alone
35
MwNT coated with  
nerve growth factors
Controls differentiation and survival of neurons 36
Purified MWNT Promotes dendrite elongation and signal processing 37
Purified SWNT Improves information processing of neurons 38
SwNT, MwNT Compatible with neural stem cells, neural processes  
were developed
39
SwNT, MwNT effective delivery of neuronal stem cells,  
supports their differentiation into neurons
40
SWNT chemically modified  
with PeG
Successful regeneration of axon 41
SwNT wrapped up with  
acetylcholine
Safe delivery of drugs to the neuron 46
SwNT, MwNT effective drug delivery leads to enhanced  
anti-tumor protection
47
Amine-functionalized SwNT valuable treatment for neurodegenerative diseases,  
improves tolerance of neurons to ischemic injury
48
Amino-functionalized MwNT Diminish apoptosis in affected area,  
advances behavioral recovery
49
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Carbon nanotubes and graphene in neuroregeneration
or azide groups. Graphene-based materials generally aggre-
gate in aqueous medium containing salts, proteins, or other 
ions, and require chemical modification or functionaliza-
tion to have the desired properties. Such functionalization 
enables researchers to change the basic electrical and opti-
cal properties of graphene. These modifications also allow 
conjugation of contrast agents, antibodies, peptides, ligands, 
drugs, and genes to the surface of graphene nanoparticles. 
These chemical modifications may provide the means for 
further customization of graphene, so that it may be used to 
detect other essential physiological changes associated with 
brain metabolism.53 It has been shown that amalgamation 
of specific functional chemical groups onto graphene may 
help otherwise insoluble drugs to become soluble, while 
regaining their anticancer activity. A study by Liu et al 
established that addition of a PEG chain to graphene oxide 
(GO) nanoparticles allows further noncovalent binding of 
hydrophobic drugs through π–π stacking.54 Thus, chemical 
functionalization to modify graphene plays a vital role in 
new drug therapies designed to overcome the blood–brain 
barrier when targeting the CNS.
Graphene in neuroregeneration
Studies in animal models of peripheral nerve transection 
indicate that electrical stimulation at lower frequencies 
of approximately 2 Hz has a favorable effect on neuronal 
regrowth.55 Because of the electrical characteristics of gra-
phene, it is suitable for the design of electroactive scaffolds 
that may be able to transmit the externally applied electrical 
signal to promote neuroregeneration.56 It has been proposed 
that three-dimensional porous graphene scaffolds provide a 
unique environment for future neuroregenerative therapies 
relating to NSCs. These porous scaffolds have been shown to 
improve the differentiation of NSCs and functional neurons.57 
Sahni et al showed high compatibility between immobilized 
graphene surfaces and neurons, which was confirmed by the 
response of the neuronal cells to the surface of graphene. 
Such graphene surfaces were adhered to uncoated poly 
(D-lysine) surfaces, with reduced cytotoxicity.58 In a culture 
model of the mouse hippocampus, it was shown that graphene 
scaffolds are not only compatible with a neural interface but 
also increase branching and regrowth of the neuronal circuit 
when compared with conventional strategies. Graphene scaf-
folds increased neuronal cell counts and the average length 
of the neuron 7 days after cell seeding when compared with 
neuron cultures on a polystyrene substrate. Western blot 
analysis also confirmed that graphene established higher lev-
els of growth associated protein 43, an indicator of neuronal 
growth.59 Even though some studies have suggested that 
graphene scaffolds have satisfactory biocompatibility with 
neuronal elements, some biocompatibility issues remain, 
in particular regarding the use of granulated GO-based or 
graphene-based nanoparticles. Wang et al demonstrated 
that lower doses (0.10–0.25 mg) of soluble GO were not 
noticeably toxic in mice, but higher doses (approximately 
0.40 mg) did cause some toxicity due to granuloma for-
mation in the lung, liver, spleen, and kidneys.60 In addi-
tion, there was significant cytotoxicity when fibroblasts 
were cultured at higher doses of graphene (.50 mg/mL), 
with graphene particles penetrating into the lysosomes, 
mitochondria, endoplasm, and cell nuclei, causing poor cell 
adhesion. Another study suggested that the irregular edges 
and protrusions generally present in graphene microsheets 
may penetrate cells. These features of graphene raise some 
safety concerns because sharp edges may potentially lead to 
disruption of the cytoskeleton, impaired cell motility, and 
other harmful effects.61 Specific developments in neuroregen-
eration may result if the high penetration capacity of graphene 
layers is carefully explored in the experimental setting.
The brain–computer interface, also known as the brain–
machine interface, is a leading field of research which 
significantly benefits graphene-based technologies. This 
technology attempts to combine neural signal processing and 
advanced robotic engineering to assist patients with stroke, 
spinal cord injury, or limb loss. Artificial patient-controlled 
prosthetic devices and artificial simulation of the CNS play 
a major role in this developing technology.62 The electrical 
fields not only stimulate nerves but also perform therapeutic 
function and help to regenerate central and peripheral nerves. 
The therapeutic role of electrical simulation has been experi-
mentally proven to increase growth rates, promote alignment 
of astrocytes, initiate myelin repair, and improve the spinal 
cord’s function after injury.63
Graphene in drug delivery
The high specific surface area, π–π stacking, and electrostatic 
or hydrophobic interactions of graphene can be exploited to 
achieve high drug loading of poorly soluble drugs without 
compromising potency and efficiency. Graphene and GO, 
with their advantageous properties, have recently emerged 
as new and competitive drug delivery systems with the 
potential to be applied in systemic, targeted, and local drug 
delivery systems.64 More efficient and safe gene and drug 
delivery vectors are required to treat genetic disorders like 
PD, AD, cystic fibrosis, and cancer, and the DNA should be 
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The carbon allotrope graphene has been investigated as a 
vector for gene, gene-drug, and protein delivery. In one 
experiment, graphene was functionalized with the cationic 
polymer PEI and used for delivery of drugs. PEI is a non-viral 
gene vector that has strong electrostatic interaction with the 
negatively charged phosphates of RNA and DNA and may 
be chemically modified. Chemical modification of PEI leads 
to increased transfection efficacy and cell selectivity, and 
a decrease in cytotoxicity. However, the biocompatibility 
of PEI remains a limitation to its biomedical application.66 
Chen et al used PEI-functionalized GO for gene delivery and 
found that the cytotoxicity of PEI-GO was much better than 
that of PEI alone. PEI-functionalized GO helped to achieve 
high transfection of gene-drug.67 In recent studies, graphene 
foams have been used as three-dimensional scaffolds in NSC 
cultures. These foams were found to be capable of electrically 
stimulating NSCs and to promote proliferation and differentia-
tion of NSCs.57 The documented findings related applications 
of graphene in neuroregeneration are shown in Table 2.
Discussion
Neuroprotection and neuroregeneration are the subject of a 
vast and dynamic field of research. The elderly population is 
the main target in the case of neurodegeneration, with ageing 
of the brain as a principal factor. Study of the cellular and 
molecular mechanisms involved in the neurodegeneration 
and neuroregeneration of the ageing brain could unmask new 
therapeutic approaches to reduce the degradation of neurons. 
Successful management of AD and PD may be achieved 
by developing novel and efficient therapies that sustain the 
self-repair ability of the brain.
On the basis of the studies reported in the literature, a wide 
range of nanotechnologies has been designed to assess the 
functional outcomes of CNTs and graphene when used as scaf-
folds to provide mechanical support for neural tissues, and to 
deliver drugs, nerve growth factors, antibodies, and proteins to 
a particular area of the brain in AD and PD to stimulate regen-
eration of neurons (Figure 3). Nanotechnological solutions 
based on CNT and graphene could be expensive to implement 
Table 2 Findings of the applications of graphene in neuroregeneration
Form of graphene Findings References
Graphene scaffold Allows conjugation with pharmacologically  
active molecules 
52
Modified graphene nanoparticles Customized graphene structure detects  
variations in brain metabolism
53
Graphene modified with PEG Increases solubility and allows attachment  
of hydrophobic drugs
54
Graphene in electrical stimulation excellent electroconductive properties  
of graphene stimulates neuronal growth
55
Graphene scaffold electrical stimulation enhances  
neuroregeneration
56
Porous graphene scaffold enhances differentiation of neural stem cells 57
Immobilized graphene Outstanding biocompatibility with neurons 58
Graphene scaffold Improves neuronal outgrowth and length  
of neuron
Higher level of growth protein
59
Graphene oxide High doses causes chronic toxicity  
due to formation of granuloma
60
Graphene microsheets Irregular edges penetrate the cell, leading  
to impaired cell motility and cytoskeletal disruption
61
Graphene in neuroprosthetics Stimulates CNS artificially to regain neural signal  
processing and function
62
Graphene in electrical stimulation Directs alignment of astrocytes and initiates  
myelin repair
63
Graphene and graphene oxide excellent targeted and local drug delivery  
due to their advantageous properties 
64
Graphene Protects DNA from degradation 65
Graphene functionalized with  
polyethylenimine
Increased transfection efficiency and reduced  
cytotoxicity
66
Graphene oxide functionalized with  
polyethylenimine
Increased transfection efficiency  
and reduced cytotoxicity
67
Graphene scaffold Supports neural stem cell proliferation  
and differentiation
57
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Carbon nanotubes and graphene in neuroregeneration
Figure 3 Overall scheme of carbon nanotube, graphene, and graphene oxide for nanotherapeutic drug delivery.
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for neuroprotection and neuroregeneration, so researchers 
should be looking at the cost-effectiveness of treatments for 
neural disorders that involve use of CNT and graphene.
Some in vivo studies have assessed the toxic effects 
of CNTs that have accidentally penetrated the body and 
probably translocated in the CNS. CNT have been reported 
to have toxic effects on dorsal root ganglion neurons and 
to induce membrane damage.68,69 On the other hand, the 
irregular edges of graphene may penetrate the cells, leading 
to cytoskeletal disruption, with higher doses causing granu-
loma in the lungs, kidneys, and liver. In addition to these 
limitations, use of CNT and graphene is steadily increasing 
worldwide. The potentially toxic outcomes of using CNT and 
graphene need to be studied in depth in mouse hippocampal 
neuron models before we embark on clinical trials, to prevent 
adverse clinical and environmental effects.
Functionalized CNTs provide enhanced solubility, and 
improve biocompatibility and mechanical properties. The 
π–π stacking and large surface area of modified graphene 
potentially enable it to be used for local and targeted drug 
delivery in AD and PD, and with reduced toxicity. The 
improved cytocompatibility of CNTs and graphene after 
functionalization is shown in Figure 4. Toxicity issues must 
be overcome to fulfill the promise of CNTs and graphene 
for nanotechnological application in neuroscience. Further 
research may show that the effectiveness of nanotechnologies 
can outweigh their risks, and the next decade will present 
huge scope for developing and delivering technologies in 
the field of neuroscience.
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